Inhibition of SLC4A4 in combination with immune checkpoint inhibitor treatment was applicable to overcome immunotherapy resistance and to prolong the survival of pancreatic adenocarcinoma bearing mice [48]. This evidence concerns the gene SLC4A4 and pancreatic adenocarcinoma.